scispace - formally typeset
S

Simeon Metallidis

Researcher at Aristotle University of Thessaloniki

Publications -  79
Citations -  1742

Simeon Metallidis is an academic researcher from Aristotle University of Thessaloniki. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 14, co-authored 49 publications receiving 821 citations. Previous affiliations of Simeon Metallidis include AHEPA University Hospital.

Papers
More filters
Journal ArticleDOI

Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.

TL;DR: A role for colchicine in the treatment of patients with coronavirus disease 2019 is suggested, with results suggesting a smaller increase in dimerized plasma fragment D compared with patients in the control group.
Journal ArticleDOI

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.

Evdoxia Kyriazopoulou, +64 more
- 03 Sep 2021 - 
TL;DR: The SAVE-MORE trial as discussed by the authors evaluated the efficacy and safety of anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure.
Journal ArticleDOI

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

TL;DR: When administered with standard of care including remdesivir, SARS-CoV-2 hIVIG did not demonstrate efficacy among patients hospitalised with COVID-19 without end-organ failure and there was evidence of heterogeneity of the treatment effect for the day 7 composite safety outcome.
Journal ArticleDOI

Penetration of Moxifloxacin and Levofloxacin into Cancellous and Cortical Bone in Patients Undergoing Total Hip Arthroplasty

TL;DR: The concentrations for both quinolones were above the minimum inhibitory concentration (MIC90s) for the most common pathogens, so they can be used for the treatment of osteomyelitis.